Health-care company stocks fell as investors shifted into riskier sectors of the market. GSK struck a deal to buy the rights to CureVac's Covid-19 and flu vaccines for up to $1.56 billion in a bid to regain ground lost to newcomers during the pandemic. The approval of Eli Lilly's new Alzheimer's drug will hasten the transformation of treatment of the dementia-causing condition, The Wall Street Journal reported. With drugs such as Kisunla coming online, Alzheimer's treatment promises to slow the cognitive decline, if only modestly, and to become more widely used. Write to Patrick Sullivan at patrick.sullivan@wsj.com(END) Dow Jones NewswiresJuly 03, 2024 16:29 ET (20:29 GMT)Copyright (c) 2024 Dow Jones & Company, Inc.

Source: Wall Street Journal July 03, 2024 20:36 UTC